GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes

Abstract

These exploratory findings provide evidence of the glucose-dependent insulinotropic potential of the GPR40 agonist TAK-875, and the promising clinical changes support future longer term clinical investigation.